KPTI Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -78.17% compared to Karyopharm Therapeutics's net margin of -49.65%. Karyopharm Therapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Karyopharm Therapeutics has a consensus price target of $28.93, signalling upside risk potential of 535.79%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 22.83%. Given that Karyopharm Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Karyopharm Therapeutics is more attractive than NovaBay Pharmaceuticals.

Karyopharm Therapeutics has a beta of 0.244, which suggesting that the stock is 75.606% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $30M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Karyopharm Therapeutics's net income of -$23.5M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.28x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Nanoviricides has a net margin of -78.17% compared to Karyopharm Therapeutics's net margin of --. Karyopharm Therapeutics's return on equity of -- beat Nanoviricides's return on equity of --.

Karyopharm Therapeutics has a consensus price target of $28.93, signalling upside risk potential of 535.79%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 365.95%. Given that Karyopharm Therapeutics has higher upside potential than Nanoviricides, analysts believe Karyopharm Therapeutics is more attractive than Nanoviricides.

Karyopharm Therapeutics has a beta of 0.244, which suggesting that the stock is 75.606% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.882, suggesting its less volatile than the S&P 500 by 11.802%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $30M, which are larger than Nanoviricides quarterly revenues of --. Karyopharm Therapeutics's net income of -$23.5M is lower than Nanoviricides's net income of -$2.2M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.28x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

Oragenics has a net margin of -78.17% compared to Karyopharm Therapeutics's net margin of --. Karyopharm Therapeutics's return on equity of -- beat Oragenics's return on equity of --.

Karyopharm Therapeutics has a consensus price target of $28.93, signalling upside risk potential of 535.79%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 2012.89%. Given that Oragenics has higher upside potential than Karyopharm Therapeutics, analysts believe Oragenics is more attractive than Karyopharm Therapeutics.

Karyopharm Therapeutics has a beta of 0.244, which suggesting that the stock is 75.606% less volatile than S&P 500. In comparison Oragenics has a beta of 0.946, suggesting its less volatile than the S&P 500 by 5.446%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $30M, which are larger than Oragenics quarterly revenues of --. Karyopharm Therapeutics's net income of -$23.5M is lower than Oragenics's net income of -$2.2M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.28x versus 0.45x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

Theriva Biologics has a net margin of -78.17% compared to Karyopharm Therapeutics's net margin of --. Karyopharm Therapeutics's return on equity of -- beat Theriva Biologics's return on equity of --.

Karyopharm Therapeutics has a consensus price target of $28.93, signalling upside risk potential of 535.79%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1294.42%. Given that Theriva Biologics has higher upside potential than Karyopharm Therapeutics, analysts believe Theriva Biologics is more attractive than Karyopharm Therapeutics.

Karyopharm Therapeutics has a beta of 0.244, which suggesting that the stock is 75.606% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $30M, which are larger than Theriva Biologics quarterly revenues of --. Karyopharm Therapeutics's net income of -$23.5M is lower than Theriva Biologics's net income of -$4.3M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.28x versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.